Amendment of regulation 37 (manufacturing and assembly)U.K.
28.—(1) Regulation 37 M1 is amended as follows.
[F1(1A) In paragraph (2), after “Good Manufacturing Practice Directive” insert “which apply under or by virtue of regulation B17”.]
[F2(2) For paragraph (4)(b) substitute—
“(b)that unless the active substance is imported into Great Britain from a country other than an approved country for import or into Northern Ireland from a country other than an EEA State from a third country, any manufacturers, importers or distributors supplying active substances to the licence holder—
(i)in the case of a product imported into Great Britain, are registered with the appropriate authority for the registration of such persons in the approved country for import, and
(ii)in the case of a product imported into Northern Ireland, are registered with the competent authority of a member State in which they are established; and”.]
[F3(3) In paragraph (5)(b), after “as described” insert “in the case of a product for sale or supply in Great Britain, in the guidelines which apply under or by virtue of regulation C17 and, in the case of a product for sale or supply in Northern Ireland,]
[F4(4) For paragraph (6)(b) substitute—
“(b)in the case of a product for sale or supply—
(i)in Great Britain, the UKMA(GB), UKMA(UK), COR(GB), COR(UK), THR(GB) or THR(UK), or
(ii)in Northern Ireland, the UKMA(NI), UKMA(UK), COR(NI), COR(UK), THR(NI), THR(UK), EU marketing authorisations or Article 126a authorisations,
applying to the medicinal products.”.]
(5) In paragraph (9)(a), from “Commission” to the end substitute “ the Blood Quality and Safety Regulations 2005 M2; or ”.
(6) In paragraph (11)—
(a)for “competent authority of a member State” substitute “ licensing authority ”; and
(b)insert “ UK ” before “marketing authorisation”.
Textual Amendments
F1Reg. 28(1A) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 18(a)
F2Reg. 28(2) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 18(b)
F3Reg. 28(3) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 18(c)
F4Reg. 28(4) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 18(d)
Commencement Information
I1Reg. 28 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
Marginal Citations
M1Regulation 37 was substituted by S.I. 2013/1855.
M2S.I. 2005/50. It has been amended by S.I. 2005/1098 and 2898, 2006/2013, 2007/604, 2008/525 and 941, 2009/372 and 3307, 2010/554, 2016/604, 2017/1320 and 2018/231.